You have not yet registered? Get your account for free.
Forgot Password? We will send you a reset link
14 March 2024
HepaRegeniX publishes data for its first-in-class MKK4 inhibitor HRX-215 for the treatment of acute and chronic liver diseases in Cell
23 November 2022
HepaRegeniX appoints Dr. Andreas Busch as Senior Advisor
12 May 2022
HepaRegeniX reports positive topline results of its Phase 1 Clinical Trial of HRX-0215, a First-In-Class MKK4 inhibitor
30 March 2022
HepaRegeniX appoints Elias Papatheodorou as new Chairman of the Board of Directors
4 November 2021
HepaRegeniX to present key results on MKK4 inhibitors and their therapeutic efficacy at upcoming scientific conferences
20 October 2021
HepaRegeniX initiates a preclinical collaboration with the Netherlands Cancer Institute to explore the potential of its 2nd MKK4 inhibitor HRX-0233 for use in cancer combination ther